All In Biotech

Drug Trial Radar · NCT03516214

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Apr 25, 2018

Primary completion

Sep 30, 2022

Study completion Nov 27, 2023

Sponsor

Lead sponsor
University of CologneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB or IV) lung cancer patients with activating mutations in the epithelial growth factor receptor (EGFR).

Conditions

  • Bronchial Neoplasms

Interventions

  • EGF816Drug

    Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.

  • TrametinibDrug

    Continuous oral treatment (once daily) with the MEK inhibitor trametinib.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting-toxicities (DLT) of the combination of EGF816 and trametinib to assess the maximum tolerated dose (MTD)/recommended phase II dose (RP2D)Time frame: Approximately one and a half years (from FPFV until the end of the DLT period of the last patient included into the trial or until death of the last patient, whichever occurs first)

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University Hospital of Cologne

    Cologne, Germany

  • University Hospital Dresden

    Dresden, Germany

  • University Hospital Essen

    Essen, Germany

  • University Hospital Frankfurt

    Frankfurt, Germany

  • University Hospital Würzburg

    Würzburg, Germany

  • Instituto Oncológico Dr. Rosell

    Barcelona, Spain

  • Vall d'Hebron University Hospital

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.